OTC Markets OTCPK - Delayed Quote USD

PureTech Health plc (PRTCY)

16.01 +0.70 (+4.57%)

As of 9:52:34 AM EST. Market Open.

Loading Chart for PRTCY

Chart Range Bar

Interval:

In partnership with ChartIQ

PureTech Health gets Panmure Liberum ‘buy’ on value and cash returns

PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category

PureTech Founded Entity Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer

Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer

$PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026$

PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

$PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026$

PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026

PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026

U.S. markets close in 29m